Search alternatives:
significant groups » significant group (Expand Search), significant gradual (Expand Search), significant amount (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
significant groups » significant group (Expand Search), significant gradual (Expand Search), significant amount (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
-
1
Between groups comparison of BTT and threshold in control, tinnitus and PBMT groups.
Published 2024Subjects: -
2
Between-groups comparison of GIN and PPI values in control, tinnitus and PBMT groups.
Published 2024Subjects: -
3
-
4
-
5
-
6
-
7
-
8
Histopathological changes in pre-treated group, treated group and normal diet group.
Published 2025Subjects: -
9
Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…</p>Results<p>Statistically significant reductions in skin lesion scores, S. aureus load, and AD-related immune mediators (i.e., IgE, TSLP, IL-33) were observed in the Staphyrase<sup>®</sup> group relative to the model group. …”
-
10
Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…</p>Results<p>Statistically significant reductions in skin lesion scores, S. aureus load, and AD-related immune mediators (i.e., IgE, TSLP, IL-33) were observed in the Staphyrase<sup>®</sup> group relative to the model group. …”
-
11
Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…</p>Results<p>Statistically significant reductions in skin lesion scores, S. aureus load, and AD-related immune mediators (i.e., IgE, TSLP, IL-33) were observed in the Staphyrase<sup>®</sup> group relative to the model group. …”
-
12
Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx
Published 2025“…</p>Results<p>Statistically significant reductions in skin lesion scores, S. aureus load, and AD-related immune mediators (i.e., IgE, TSLP, IL-33) were observed in the Staphyrase<sup>®</sup> group relative to the model group. …”
-
13
Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…</p>Results<p>Statistically significant reductions in skin lesion scores, S. aureus load, and AD-related immune mediators (i.e., IgE, TSLP, IL-33) were observed in the Staphyrase<sup>®</sup> group relative to the model group. …”
-
14
Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…</p>Results<p>Statistically significant reductions in skin lesion scores, S. aureus load, and AD-related immune mediators (i.e., IgE, TSLP, IL-33) were observed in the Staphyrase<sup>®</sup> group relative to the model group. …”
-
15
Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…</p>Results<p>Statistically significant reductions in skin lesion scores, S. aureus load, and AD-related immune mediators (i.e., IgE, TSLP, IL-33) were observed in the Staphyrase<sup>®</sup> group relative to the model group. …”
-
16
Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…</p>Results<p>Statistically significant reductions in skin lesion scores, S. aureus load, and AD-related immune mediators (i.e., IgE, TSLP, IL-33) were observed in the Staphyrase<sup>®</sup> group relative to the model group. …”
-
17
-
18
-
19
-
20